These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17335939)

  • 1. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
    Dessalew N; Bharatam PV
    Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
    Patel DS; Bharatam PV
    Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
    Caballero J; Fernández M; González-Nilo FD
    Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D QSAR studies on GSK-3 inhibition by aloisines.
    Zeng M; Jiang Y; Zhang B; Zheng K; Zhang N; Yu Q
    Bioorg Med Chem Lett; 2005 Jan; 15(2):395-9. PubMed ID: 15603961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
    Kamath S; Buolamwini JK
    J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of potent and selective bisarylmaleimide GSK3 inhibitors.
    Engler TA; Malhotra S; Burkholder TP; Henry JR; Mendel D; Porter WJ; Furness K; Diefenbacher C; Marquart A; Reel JK; Li Y; Clayton J; Cunningham B; McLean J; O'toole JC; Brozinick J; Hawkins E; Misener E; Briere D; Brier RA; Wagner JR; Campbell RM; Anderson BD; Vaughn R; Bennett DB; Meier TI; Cook JA
    Bioorg Med Chem Lett; 2005 Feb; 15(4):899-903. PubMed ID: 15686883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
    AbdulHameed MD; Hamza A; Liu J; Zhan CG
    J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
    Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
    J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
    Martinez A; Alonso M; Castro A; Dorronsoro I; Gelpí JL; Luque FJ; Pérez C; Moreno FJ
    J Med Chem; 2005 Nov; 48(23):7103-12. PubMed ID: 16279768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
    Xiao J; Guo Z; Guo Y; Chu F; Sun P
    Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
    Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
    J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
    Mascarenhas NM; Ghoshal N
    Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening.
    Dessalew N; Bharatam PV
    Biophys Chem; 2007 Jul; 128(2-3):165-75. PubMed ID: 17482749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
    Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
    J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.